{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '780 Memorial Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.63,
 'askSize': 800,
 'averageDailyVolume10Day': 168812,
 'averageVolume': 263622,
 'averageVolume10days': 168812,
 'beta': 2.397485,
 'beta3Year': None,
 'bid': 4.72,
 'bidSize': 800,
 'bookValue': 4.48,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.02,
 'dayLow': 4.75,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 0.876,
 'enterpriseToRevenue': 0.275,
 'enterpriseValue': 37634024,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '888 459 2940',
 'fiftyDayAverage': 6.0512857,
 'fiftyTwoWeekHigh': 10,
 'fiftyTwoWeekLow': 2.79,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 17042891,
 'forwardEps': -2.52,
 'forwardPE': -1.9285715,
 'fromCurrency': None,
 'fullTimeEmployees': 131,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.12883,
 'heldPercentInstitutions': 0.74639,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/jouncetx.com',
 'longBusinessSummary': 'Jounce Therapeutics, Inc., a clinical-stage '
                        'immunotherapy company, develops therapies for the '
                        'treatment of cancer. The company offers vopratelimab, '
                        'a clinical-stage monoclonal antibody that binds to '
                        'and activates the Inducible T cell CO-Stimulator, a '
                        'protein on the surface of T cells found in various '
                        'solid tumors, which is in Phase II clinical trial for '
                        'the treatment of PD-1/PD-L1 inhibitor patients with '
                        'non-small cell lung cancer and urothelial cancer. It '
                        'is also developing JTX-4014, a clinical-stage '
                        'anti-PD-1 antibody for combination therapy; and '
                        'JTX-1811, a monoclonal antibody designed to '
                        'selectively deplete T regulatory cells in the tumor '
                        'microenvironment that is in the IND-enabling phase. '
                        "The company's product candidate includes JTX-8064, an "
                        'antibody that binds to leukocyte immunoglobulin like '
                        'receptor B2, which is a cell surface receptor '
                        'expressed on macrophages. Jounce Therapeutics, Inc. '
                        'was incorporated in 2012 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'Jounce Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 165498064,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_228489698',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 42757000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.02,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 259 3840',
 'previousClose': 5.07,
 'priceHint': 4,
 'priceToBook': 1.0848215,
 'priceToSalesTrailing12Months': 1.2089769,
 'profitMargins': 0.31234,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.02,
 'regularMarketDayLow': 4.75,
 'regularMarketOpen': 5.02,
 'regularMarketPreviousClose': 5.07,
 'regularMarketPrice': 5.02,
 'regularMarketVolume': 207002,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 34053100,
 'sharesPercentSharesOut': 0.0463,
 'sharesShort': 1575119,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1472032,
 'shortName': 'Jounce Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0922,
 'shortRatio': 5.29,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'JNCE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.24,
 'trailingPE': 3.919355,
 'twoHundredDayAverage': 5.5279856,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'de2707b3-20d6-342c-a060-623e25598a15',
 'volume': 207002,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://jouncetx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}